| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Huda Salem AlSalem, Sara Naif Alharbi, Mona Saad Binkadem, Soha Talal Al-Goul, Ahmed A Abu-Hassan, Mohamed Oraby, Mohamed A Abdel-Latee. A nano-level assay of tizanidine using the fluorogenic character of benzofurazan derivative: Application to plasma, tablets, and content homogeneity evaluation. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. vol 320. 2024-06-08. PMID:38850823. |
people frequently administer tizanidine (tiz) to treat spasticity resulting from diseases like multiple sclerosis or spinal cord injuries. |
2024-06-08 |
2024-06-11 |
Not clear |
| Vamshi Krishna Jogiraju, Tycho Heimbach, Yuliana Toderika, David R Taf. Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption. Drug metabolism and pharmacokinetics. vol 37. 2021-10-19. PMID:33561738. |
tizanidine is an alpha2-adrenergic agonist, used to treat spasticity associated with multiple sclerosis and spinal injury. |
2021-10-19 |
2023-08-13 |
human |
| Sergio del Río-Sancho, Virginia Merino, Alicia López-Castellano, Yogeshvar N Kali. A UHPLC-UV Method to Quantify Skin Deposition and Transdermal Permeation of Tizanidine Hydrochloride. Journal of chromatographic science. vol 54. issue 5. 2016-12-30. PMID:26892401. |
tizanidine hydrochloride is an α2-adrenergic agonist used for the symptomatic relief of spasticity associated with multiple sclerosis or with spinal cord injury or disease. |
2016-12-30 |
2023-08-13 |
Not clear |
| Veronika Vakhapova, Eitan Auriel, Arnon Karn. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. Clinical neuropharmacology. vol 33. issue 3. 2010-08-31. PMID:20502134. |
nightly sublingual tizanidine hcl in multiple sclerosis: clinical efficacy and safety. |
2010-08-31 |
2023-08-12 |
Not clear |
| Leonard Kamen, Herbert R Henney, Jacob D Runya. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Current medical research and opinion. vol 24. issue 2. 2008-02-28. PMID:18167175. |
tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (ms), stroke, and spinal cord injury (sci). |
2008-02-28 |
2023-08-12 |
Not clear |
| Roger Chou, Kim Peterson, Mark Helfan. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. Journal of pain and symptom management. vol 28. issue 2. 2004-09-07. PMID:15276195. |
there is fair evidence that baclofen, tizanidine, and dantrolene are effective compared to placebo in patients with spasticity (primarily multiple sclerosis). |
2004-09-07 |
2023-08-12 |
Not clear |
| L Groves, M K Shellenberger, C S Davi. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Advances in therapy. vol 15. issue 4. 1998-12-09. PMID:10186943. |
within the limits of these comparisons, tizanidine, baclofen, and diazepam were equally effective in decreasing excessive muscle tone in patients with multiple sclerosis or cerebrovascular lesions. |
1998-12-09 |
2023-08-12 |
Not clear |
| J M Gracies, P Nance, E Elovic, J McGuire, D M Simpso. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle & nerve. Supplement. vol 6. 1998-12-04. PMID:9826984. |
it appears preferable to use centrally acting drugs such as baclofen, tizanidine, and diazepam in spasticity of spinal origin (spinal cord injury and multiple sclerosis), whereas dantrolene sodium, due to its primarily peripheral mechanism of action, may be preferable in spasticity of cerebral origin (stroke and traumatic brain injury) where sensitivity to sedating effects is generally higher. |
1998-12-04 |
2023-08-12 |
Not clear |
| P W Nance, W A Sheremata, S G Lynch, T Vollmer, S Hudson, G S Francis, P O'Connor, J A Cohen, R T Schapiro, R Whitham, M K Mass, J W Lindsey, K Shellenberge. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Archives of neurology. vol 54. issue 6. 1997-07-10. PMID:9193208. |
relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. |
1997-07-10 |
2023-08-12 |
Not clear |
| C Smith, G Birnbaum, J L Carter, J Greenstein, F D Lubli. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. vol 44. issue 11 Suppl 9. 1994-12-29. PMID:7970009. |
tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. |
1994-12-29 |
2023-08-12 |
Not clear |
| A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology. vol 44. issue 11 Suppl 9. 1994-12-29. PMID:7970014. |
a double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. |
1994-12-29 |
2023-08-12 |
Not clear |
| M Emre, G C Leslie, C Muir, N J Part, R Pokorny, R C Robert. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). Journal of neurology, neurosurgery, and psychiatry. vol 57. issue 11. 1994-12-08. PMID:7964811. |
in a double blind, placebo controlled, cross over study the correlations between single doses (2, 4, and 8 mg), plasma concentrations, and antispastic action of tizanidine were investigated in 16 patients with extensor spasticity of the legs due to multiple sclerosis. |
1994-12-08 |
2023-08-12 |
Not clear |
| G P Ric. Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 16. issue 4. 1989-12-20. PMID:2804809. |
tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis. |
1989-12-20 |
2023-08-11 |
Not clear |
| M Pellkofer, M Pauli. [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities]. Medizinische Klinik (Munich, Germany : 1983). vol 84. issue 1. 1989-03-30. PMID:2645508. |
in a double-blind comparative study, the therapeutic efficacy and safety of three centrally effective antispasmodics (tetrazepam, baclofen and tizanidine) in patients suffering from multiple sclerosis with spastic motor disturbances of the lower extremities was to be examined. |
1989-03-30 |
2023-08-11 |
Not clear |
| M Eyssette, F Rohmer, G Serratrice, J M Warter, D Boisso. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Current medical research and opinion. vol 10. issue 10. 1988-07-12. PMID:3286128. |
a multi-centre, double-blind study was carried out in 100 patients suffering from chronic spasticity due to multiple sclerosis to compare the effectiveness of tizanidine hydrochloride with that of baclofen. |
1988-07-12 |
2023-08-11 |
Not clear |
| M Eyssette, F Rohmer, G Serratrice, J M Warter, D Boisso. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Current medical research and opinion. vol 10. issue 10. 1988-07-12. PMID:3286128. |
multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. |
1988-07-12 |
2023-08-11 |
Not clear |
| M Eyssette, F Rohmer, G Serratrice, J M Warter, D Boisso. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Current medical research and opinion. vol 10. issue 10. 1988-07-12. PMID:3286128. |
thus, tizanidine is a well tolerated and effective muscle relaxant, the antispastic efficacy of which is well maintained over time, and it promises to be particularly useful in the treatment of spasticity due to multiple sclerosis. |
1988-07-12 |
2023-08-11 |
Not clear |
| M C Hoogstraten, R J van der Ploeg, W vd Burg, A Vreeling, S van Marle, J M Minderhou. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta neurologica Scandinavica. vol 77. issue 3. 1988-06-27. PMID:3376747. |
sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study. |
1988-06-27 |
2023-08-11 |
Not clear |
| M C Hoogstraten, R J van der Ploeg, W vd Burg, A Vreeling, S van Marle, J M Minderhou. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta neurologica Scandinavica. vol 77. issue 3. 1988-06-27. PMID:3376747. |
tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. |
1988-06-27 |
2023-08-11 |
Not clear |
| B Bass, B Weinshenker, G P Rice, J H Noseworthy, M G Cameron, W Hader, S Bouchard, G C Eber. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 15. issue 1. 1988-04-21. PMID:3345456. |
tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. |
1988-04-21 |
2023-08-11 |
Not clear |